News
March 23, 2026
Investor
Supplementary Materials of Consolidated Financial Results for the Six Months Ended January 31, 2026 
March 13, 2026
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending July 2026
March 13, 2026
Investor
[Summary]Consolidated Financial Results for the Six Months Ended January 31, 2026 (Based on Japanese GAAP)
February 16, 2026
Investor
Notice Concerning Dividends of Surplus (Interim Dividend)
December 11, 2025
Investor
Supplementary Materials of Consolidated Financial Results for the Three Months Ended October 31 2025
December 11, 2025
Investor
[Summary]Consolidated Financial Results for the Three Months Ended October 31, 2025 (Under Japanese GAAP)
November 17, 2025
Investor
Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation
November 13, 2025
Research and Development
Pharma Foods Partners with The University of Tokyo For Next-Generation Antibody Drug Discovery ～A Leap Forward with AI and Advanced Molecular Engineering～
September 30, 2025
Investor
Notice of the 28th Annual General Meeting of Shareholders
September 25, 2025
Investor
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)
March 13, 2026
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending July 2026
March 13, 2026
Investor
[Summary]Consolidated Financial Results for the Six Months Ended January 31, 2026 (Based on Japanese GAAP)
February 16, 2026
Investor
Notice Concerning Dividends of Surplus (Interim Dividend)
December 11, 2025
Investor
Supplementary Materials of Consolidated Financial Results for the Three Months Ended October 31 2025
December 11, 2025
Investor
[Summary]Consolidated Financial Results for the Three Months Ended October 31, 2025 (Under Japanese GAAP)
November 17, 2025
Investor
Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation
November 13, 2025
Research and Development
Pharma Foods Partners with The University of Tokyo For Next-Generation Antibody Drug Discovery ～A Leap Forward with AI and Advanced Molecular Engineering～
September 30, 2025
Investor
Notice of the 28th Annual General Meeting of Shareholders
September 25, 2025
Investor
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)